Angelini Ventures co-leads €20 million Series A financing in Neumirna Therapeutics to Develop Next-Generation RNA ...
Angelini Ventures co-leads alongside Invivo Partners with participation from Innovestor’s Life Science Fund and other existing investors Financing will support clinical development of Neumirna‘s lead asset NMT.001, a potential disease-modifying …